Autonomix Medical reports Q3 FY2025 net loss of $2.7M, cash $11.8M; PoC trial data on track for 1H2025

Autonomix Medical, Inc.

Net loss of $2.7M for Q3 ended Dec 31, 2024 vs $3.1M a year ago; nine-month net loss $8.2M vs $10.0M.
Cash position $11.8M as of Dec 31, 2024; raised $10M in underwritten public offering during the quarter.
Topline proof-of-concept trial data for pancreatic cancer pain expected in 1H2025; US clinical trials targeted for 2H2025.
Achieved design lock for RF ablation catheter after successful animal testing; expanded IP with new U.S. patent grant.
Targeting De Novo submission in 2026 and potential FDA clearance for pancreatic cancer pain in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.